Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK3 | Q13188 | 8/20 | 0.85 |
| ▸ | STK4 | Q13043 | 7/20 | 0.84 |
| ▸ | EGFR | P00533 | 11/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.78 |
| ▸ | BTK | Q06187 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | STK25 | O00506 | 1/20 | 0.75 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.75 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.75 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.75 |
| ▸ | STK17B | O94768 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384343 | 1.00 | STK3 (0.85) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL29801566 | 0.94 | STK3 (0.86) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL2387968 | 0.94 | STK3 (0.86) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL10054548 | 0.92 | STK4 (0.76) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL33532011 | 0.92 | STK3 (1.00) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL2384641 | 0.92 | STK3 (1.00) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL33529039 | 0.92 | STK3 (0.83) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL2388105 | 0.92 | STK3 (0.83) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL22419770 | 0.91 | STK4 (1.00) | STK3STK4EGFRERBB2BTK | |
| SCHEMBL22419640 | 0.91 | STK4 (0.90) | STK3STK4EGFRERBB2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092046-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092046-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, MET, ERBB2 | STK3 570/4885STK4 632/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.